Skip to main content

Why Jim Cramer Would Buy Pfizer Here

Publish date:
Video Rating:
Video Duration:

Pfizer  (PFE) - Get Pfizer Inc. Report reported adjusted earnings for the three months ending in March were pegged at 86 cents per share, a 7.5% increase from the same period last year and 8 cents ahead of the Street consensus forecast. Group revenues, Pfizer said, rose 21.4% from last year to $14.6 billion, topping analysts estimates of a $13.63 billion tally.

"I am extremely proud of the way we have begun 2021, delivering strong financial results in the first quarter," said CEO Albert Bourla. "Even excluding the growth provided from BNT162b2, our revenues grew 8% operationally, which aligns with our stated goal of delivering at least a 6% compound annual growth rate through 2025. In addition, we have achieved important clinical, regulatory and commercial milestones across our pipeline and portfolio while also continuing to increase our capacity to supply urgently-needed doses of BNT162b2 to the world."

Recap TheStreet Live: Everything Jim Cramer Is Watching Tuesday

Related Videos